№ lp_1_22050
File format: docx
Character count: 84456
File size: 298 KB
Comprehensive clinical guideline for the management of stimulant use disorder including diagnostic, treatment, and management protocols for various stages of addiction and recovery.
Year:
2021
Region / city:
United States
Topic:
Stimulant use disorder, clinical guidelines
Document Type:
Clinical Practice Guideline
Organization / Institution:
ASAM, AAAP
Author:
Not specified
Target Audience:
Healthcare professionals, addiction specialists
Effective Period:
Not specified
Approval Date:
2021
Date of Revisions:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2023
Region / City:
Massachusetts
Topic:
Opioid Use Disorder, Medication Comparison
Document Type:
Clinical Guidelines
Organization / Institution:
Massachusetts Department of Public Health, Bureau of Health Care Safety & Quality
Author:
Massachusetts Department of Public Health
Target Audience:
Healthcare providers, Long-Term Care Facilities
Period of Validity:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / city:
South East London
Topic:
Shared care prescribing for narcolepsy and idiopathic hypersomnia treatment
Document type:
Medical guideline
Organization / institution:
South East London Interface Prescribing Policy
Author:
Specialist clinicians, GP teams
Target audience:
Healthcare professionals, GPs, specialists
Period of validity:
Ongoing until updated
Approval date:
Not specified
Date of amendments:
Not specified
Author:
Shawnee Dixon
Title:
ADHD Medication
Course:
Drugs, Behavior and Modern Science
Type of document:
Research Paper
Date:
August 9, 2014
Subject:
Attention Deficit Hyperactivity Disorder and prescription stimulant abuse
Key topics:
ADHD diagnosis, stimulant medications, nonmedical use, emergency department visits, side effects
Institutions referenced:
National Institute of Mental Health (NIMH); Centers for Disease Control and Prevention (CDC); National Institute of Drug Abuse (NIH); Drug Abuse Warning Network (DAWN)
Medications discussed:
amphetamine; methylphenidate; atomoxetine; lisdexamfetamine dimesylate; dextroamphetamine; methamphetamine hydrochloride
Population focus:
Children and adolescents ages 3–17; individuals using prescription stimulants nonmedically
Geographical context:
United States
Sources cited:
NIMH (2013–2014); CDC (2013); NIH (2014); DAWN (2004, 2008); American Journal of Health-System Pharmacy (2014)
Jurisdiction:
Western Australia, Australia
Responsible authority:
Department of Health
Subject:
Prescribing of stimulant medicines
Document type:
Prescribing guidance / regulatory information
Target users:
Medical practitioners authorised to prescribe stimulant medicines
Approved conditions:
ADHD; Acquired brain injury; Depression; Narcolepsy; Binge eating disorder
Approved specialists:
Paediatrician; Neurologist; Paediatric neurologist; Psychiatrist; Child and adolescent psychiatrist; Rehabilitation physician; Paediatric rehabilitation physician; Respiratory and sleep physician; Thoracic medicine physician
Patient eligibility:
Patients within specified approved age criteria depending on prescriber specialisation
Minimum patient age:
4 years (for child-specialist prescribers)
Maximum stimulant doses:
Dexamfetamine up to 60 mg/day; Lisdexamfetamine up to 70 mg/day; Methylphenidate up to 120 mg/day; combination doses calculated as dexamfetamine equivalents
Prescription setting:
Clinical treatment of approved conditions
Regulatory requirement:
Notification to the Department of Health when commencing stimulant treatment or when specified patient or prescriber details change
Co-prescriber rules:
Co-prescribers must be medical practitioners practising in Western Australia and recorded in the notification
Review requirement:
Annual patient review by the primary stimulant prescriber
Contact service:
Schedule 8 Medicines Prescriber Information Service
Telehealth provision:
Interstate practitioners may prescribe via telehealth for Western Australian residents for prescriptions issued on or after 13 December 2023
Year:
No specific year mentioned
Region / City:
No specific region or city mentioned
Topic:
Cocaine use and its effects
Document Type:
Health and safety guide
Agency / Institution:
No specific agency or institution mentioned
Author:
No author specified
Target Audience:
General public, individuals seeking information on cocaine and its effects
Period of Validity:
No specific period mentioned
Approval Date:
No approval date mentioned
Date of Changes:
No date of changes mentioned
Year:
2025
Region / City:
Massachusetts, Boston
Topic:
Healthcare, Opioid Use Disorder, Long-Term Care
Document Type:
Memorandum
Organization / Institution:
Department of Public Health
Author:
Teryl Smith, RN, MPH
Target Audience:
Long-Term Care Facility Administrators
Period of Validity:
August 14, 2025
Approval Date:
August 14, 2025
Date of Changes:
August 14, 2025
Year:
2026
Region:
North East Essex, UK
Subject:
Neurodevelopmental disorders in children and young people
Document type:
Guidance booklet
Organization:
Suffolk and North East Essex Integrated Care Board; East Suffolk North East Essex Foundation Trust (ESNEFT)
Audience:
Parents and carers of children and young people
Content focus:
Autism Spectrum Disorder (ASD), Attention Deficit Hyperactivity Disorder (ADHD), neurodiversity, diagnostic pathway, support services
Purpose:
Explanation of assessment and diagnostic pathway for neurodevelopmental disorders
Year:
2026
Region / State:
Idaho, USA
Document Type:
Program Description
Organization:
BPA Health
Target Audience:
Clients with substance use disorders, provider networks, stakeholders
Scope of Services:
Outpatient, residential, social detoxification, community-based settings, Recovery Support Services
Funding Sources:
Federal block grants, state funding, discretionary grants
Quality Focus Areas:
Accessibility, Appropriateness, Timeliness, Continuity, Effectiveness, Efficiency, Safety, Client/Provider Relationships
Compliance:
Contractor and provider regulatory and contractual adherence
Year:
2020-2025
Region / City:
Oklahoma
Theme:
Substance Use Disorder (SUD), Medicaid Expansion, Mental Health
Document Type:
State Demonstration Report
Organ / Institution:
Oklahoma State Government
Author:
Oklahoma Department of Mental Health and Substance Abuse Services (ODMHSAS)
Target Audience:
State policymakers, health service providers, Medicaid beneficiaries
Period of Validity:
12/22/2020 - 12/31/2025
Approval Date:
12/22/2020
Amendment Date:
Not specified
Year:
2022
Region / City:
Massachusetts
Subject:
Opioid Use Disorder, Long-Term Care Facilities
Document Type:
Memorandum
Agency:
Massachusetts Executive Office of Health and Human Services, Department of Public Health
Author:
Elizabeth Kelley, MPH, MBA, Director Bureau of Health Care Safety and Quality
Target Audience:
Long-Term Care Facility Administrators
Period of Validity:
September 12, 2022
Approval Date:
September 12, 2022
Note:
Year
Theme:
Substance Use Disorder Assessment
Document Type:
Intake Form
Note:
Year
Region / City:
Jacksonville
Subject:
Autism Spectrum Disorder, Emergency Response
Document Type:
Information Sheet
Agency / Institution:
Jacksonville Police and Fire Departments
Target Audience:
Individuals with Autism Spectrum Disorder, First Responders, Emergency Personnel
Year:
2008
Region / City:
N/A
Theme:
Eating Disorders
Document Type:
Questionnaire
Organization / Institution:
N/A
Author:
Fairburn, Beglin
Target Audience:
Individuals experiencing eating disorders or professionals assessing eating disorders
Period of validity:
N/A
Approval Date:
N/A
Date of revisions:
N/A
Document type:
Psychological report section
Purpose:
Application to SPED school offering National Curriculum for students with Autism Spectrum Disorder
Target population:
Children with Autism Spectrum Disorder
Intended users:
Registered Educational or Clinical psychologists
Governing body reference:
Ministry of Education, Singapore
Professional guidelines referenced:
Professional Practice Guidelines for the Psycho-educational Assessment & Placement of Students with Special Educational Needs (2018)
Clinical guidelines referenced:
Clinical Practice Guidelines on Autism Spectrum Disorder in Children and Adolescents (2023)
Jurisdiction:
Singapore
Assessment instruments referenced:
Singapore Ability Scales
Validity period of assessment:
Within 2 years from date of application
Educational context:
Special Education (SPED)
Content scope:
Psycho-educational assessment, diagnosis, developmental, educational, intervention, and medical history
Authorship requirements:
Psychologists listed in the Singapore Register of Psychologists
Year:
2025
Region / city:
Oxford, London, Newport
Subject:
Developmental Coordination Disorder (DCD)
Document type:
Guidance
Institution:
SASC
Authors:
Professor Anna Barnett, Professor Elisabeth Hill, Professor Amanda Kirby
Target audience:
Practitioners and researchers in neurodevelopmental disorders
Period of validity:
2025 onwards
Approval date:
November 2025
Date of changes:
N/A
Year:
2025-2027
Region / City:
Rural and Frontier Colorado
Topic:
Substance Use Disorder Treatment
Document Type:
Grant Program Announcement
Organization:
Rocky Mountain Health Plans, Signal Behavioral Health Network
Author:
Rocky Mountain Health Plans, Signal Behavioral Health Network
Target Audience:
Local governments, municipalities, schools, law enforcement, primary care providers, SUD treatment providers
Period of Validity:
July 1, 2025 – June 30, 2027
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2025
Region/City:
Maine
Theme:
Substance Use Disorder, Behavioral Health
Document Type:
Request for Proposal (RFP)
Institution:
Department of Health and Human Services, State of Maine
Author:
Casandra Manson
Target Audience:
Vendors and Service Providers in Substance Use Disorder Treatment
Period of Validity:
Proposal Submission Deadline: June 19, 2025
Approval Date:
Not specified
Date of Amendments:
Not specified
Year:
2013
Region / City:
Not specified
Subject:
Developmental Language Disorder (DLD)
Document Type:
Care Pathway
Organization:
Not specified
Author:
Not specified
Target Audience:
Health professionals, therapists, parents, educators
Period of validity:
Not specified
Approval Date:
Not specified
Date of last update:
Not specified